Galera Therapeutics is a private clinical-stage biotech company focused on the development of breakthrough drugs targeting the oxygen metabolic pathways. The company's lead compounds are small molecule dismutase mimetics which closely mimic the activity of the human superoxide dismutase enzymes. While the biology of the superoxide dismutase family suggests a broad range of potential applications, Galera is initially focusing its development on the prevention of radiation-induced toxicity, including mucositis, and the treatment of fibrosis and cancer.

Galera Therapeutics Raises $11 Million in Series A Financing
Galera Therapeutics, Inc. announced an $11 million Series A venture capital financing. Proceeds will be used to expand clinical development of...